Dashboard
Manage Tickers

IBRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-immunitybio-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Immu...
09/10/2025 10:57:59

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $8 price t...

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
09/08/2025 14:11:25

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybio-announces-paradigm-changing-findings-from-phase-2-quilt-3055-study-showing-anktiva-reverses-lymphopenia-in-patients-with-checkpoint-inhibitor-resistant-advanced-nsclc-with-reversal-resulting-in-significant-prolonged-mos
ImmunityBio Announces Paradigm Changing Fi...
09/08/2025 12:35:37

Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lo...

whats-going-on-with-immunitybio-shares-tuesday
What's Going On With ImmunityBio Shares Tu...
08/26/2025 16:33:41

ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease...

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
08/26/2025 16:26:10

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybios-chemotherapy-free-combo-shows-100-disease-control-in-early-glioblastoma-trial-plans-phase-2
ImmunityBio's Chemotherapy-Free Combo Show...
08/26/2025 12:34:48

First chemotherapy-free trial combining ANKTIVA, an IL-15 agonist, natural killer (NK) cell therapy, and Optune immune-stimulat...

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
08/19/2025 14:47:18

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybio-opens-new-phase-2-study-to-assess-bioshield-platform-anchored-by-anktiva-in-long-covid-patients
ImmunityBio Opens New Phase 2 Study To Ass...
08/19/2025 12:34:59

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
08/14/2025 12:35:13

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybio-announces-early-quilt-106-phase-i-data-showing-complete-responses-in-waldenstrom-macroglobulinemia-patients-treated-with-cd19-car-nk-therapy
ImmunityBio Announces Early QUILT-106 Phas...
08/13/2025 12:36:19

Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of ...

immunitybios-anktiva-now-available-at-houston-va-offering-new-bladder-cancer-treatment-for-veterans
ImmunityBio's ANKTIVA Now Available At Hou...
08/11/2025 12:33:56

ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affai...

d-boral-capital-maintains-buy-on-immunitybio-maintains-30-price-target
D. Boral Capital Maintains Buy on Immunity...
08/05/2025 12:09:23

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.

immunitybio-q2-eps-010-beats-011-estimate-sales-26425m-beat-21488m-estimate
ImmunityBio Q2 EPS $(0.10) Beats $(0.11) E...
08/05/2025 11:41:08

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) b...

d-boral-capital-maintains-buy-on-immunitybio-maintains-30-price-target
D. Boral Capital Maintains Buy on Immunity...
07/25/2025 11:47:23

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.

immunitybio-reports-60-q2-revenue-growth-to-264m-ytd-sales-of-43m-and-246-unit-growth-since-jcode-with-regulatory-updates
ImmunityBio Reports 60% Q2 Revenue Growth ...
07/25/2025 10:10:23

immunitybio-announced-registered-direct-offering-with-two-institutional-investors-with-gross-proceeds-of-approximately-80m-if-fully-exercised-the-warrants-could-result-in-additional-gross-proceeds-of-up-to-approximately-96m
ImmunityBio Announced Registered Direct Of...
07/25/2025 10:05:15

la-times-going-public-patrick-soon-shiong-plans-green-bay-style-ownership-to-democratize-143-year-old-paper
LA Times Going Public? Patrick Soon-Shiong...
07/22/2025 06:36:48

Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year.

d-boral-capital-maintains-buy-on-immunitybio-maintains-30-price-target
D. Boral Capital Maintains Buy on Immunity...
07/08/2025 11:19:21

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.

reported-earlier-immunitybio-gains-uk-marketing-authorization-for-anktiva-with-bacillus-calmette-gurin-in-bladder-cancer-expanding-breakthrough-therapy-beyond-us
Reported Earlier, ImmunityBio Gains UK Mar...
07/08/2025 06:29:51

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural kil...

hc-wainwright--co-reiterates-buy-on-immunitybio-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Immu...
06/04/2025 11:11:35

HC Wainwright & Co. analyst Andres Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $8 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION